[go: up one dir, main page]

CY1123667T1 - Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου - Google Patents

Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου

Info

Publication number
CY1123667T1
CY1123667T1 CY20201100869T CY201100869T CY1123667T1 CY 1123667 T1 CY1123667 T1 CY 1123667T1 CY 20201100869 T CY20201100869 T CY 20201100869T CY 201100869 T CY201100869 T CY 201100869T CY 1123667 T1 CY1123667 T1 CY 1123667T1
Authority
CY
Cyprus
Prior art keywords
preparation
spherine
immune
polysorbate
antibody
Prior art date
Application number
CY20201100869T
Other languages
English (en)
Inventor
David J. Burke
Shaun E. Buckley
Sherwood Russ Lehrman
Barbara Horsey O'connor
James Callaway
Christopher Phillips
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32869424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123667(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY1123667T1 publication Critical patent/CY1123667T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Περιγράφεται ένα σταθερό υδατικό φαρμακευτικό παρασκεύασμα που περιλαμβάνει μία θεραπευτικά αποτελεσματική ποσότητα ενός αντισώματος, polysorbate 80, ένα ρυθμιστικό διάλυμα το οποίο αναστέλλει την οξείδωση του πολυσορβικού μαζί με μεθόδους δημιουργίας του παρασκευάσματος. Επίσης περιγράφονται παρασκευάσματα με υψηλές συγκεντρώσεις αντισώματος τα οποία διατηρούν σταθερούς όγκους και τα οποία μπορούν να χρησιμοποιούνται σε ασθενείς κυμαινόμενου βάρους.
CY20201100869T 2003-02-10 2020-09-15 Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου CY1123667T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44581803P 2003-02-10 2003-02-10
EP10005235.6A EP2236154B1 (en) 2003-02-10 2004-02-09 Immunoglobulin formulation and method of preparation thereof
PCT/US2004/003873 WO2004071439A2 (en) 2003-02-10 2004-02-09 Immunoglobulin formulation and method of preparation thereof
EP04709508A EP1592440A4 (en) 2003-02-10 2004-02-09 IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME

Publications (1)

Publication Number Publication Date
CY1123667T1 true CY1123667T1 (el) 2022-03-24

Family

ID=32869424

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100682T CY1120574T1 (el) 2003-02-10 2018-06-29 Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου
CY20201100869T CY1123667T1 (el) 2003-02-10 2020-09-15 Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100682T CY1120574T1 (el) 2003-02-10 2018-06-29 Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου

Country Status (29)

Country Link
US (7) US20050053598A1 (el)
EP (4) EP2236154B1 (el)
JP (3) JP4728948B2 (el)
KR (1) KR20050110628A (el)
CN (2) CN1771053B (el)
AR (1) AR043144A1 (el)
AU (2) AU2004210679A1 (el)
CA (1) CA2515444C (el)
CL (1) CL2004000224A1 (el)
CY (2) CY1120574T1 (el)
DK (2) DK3417875T3 (el)
ES (1) ES2819011T3 (el)
HK (1) HK1182021A1 (el)
HU (1) HUE051878T2 (el)
IL (1) IL170008A (el)
MX (1) MXPA05008409A (el)
MY (1) MY162623A (el)
NO (1) NO346070B1 (el)
PE (1) PE20050190A1 (el)
PT (2) PT3417875T (el)
RU (1) RU2358763C2 (el)
SI (2) SI3417875T1 (el)
SK (1) SK50672005A3 (el)
TR (1) TR201808801T4 (el)
TW (1) TWI367766B (el)
UA (1) UA82685C2 (el)
UY (1) UY28184A1 (el)
WO (1) WO2004071439A2 (el)
ZA (1) ZA200506159B (el)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485127B1 (en) * 2002-02-25 2011-06-08 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
US20040115194A1 (en) * 2002-09-06 2004-06-17 Yi Wang Method of treatment of asthma using antibodies to complement component C5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
CA2515444C (en) * 2003-02-10 2014-04-01 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
TR201816556T4 (tr) * 2004-04-02 2018-11-21 Swedish Orphan Biovitrum Ab Publ Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20090202527A1 (en) * 2004-11-19 2009-08-13 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US20090238820A1 (en) * 2005-03-08 2009-09-24 Allan Corey M ANTI-MAdCAM ANTIBODY COMPOSITIONS
AU2006247039B2 (en) 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EP2354162A1 (en) * 2005-09-12 2011-08-10 Novimmune SA Anti-CD3 antibody formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
PT1971366E (pt) 2005-12-29 2014-11-06 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
BR122017024057B8 (pt) 2006-03-15 2021-05-25 Alexion Pharma Inc anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2663892A1 (en) * 2006-09-25 2008-04-03 Medimmune, Llc Stabilized antibody formulations and uses thereof
CL2007002880A1 (es) * 2006-10-06 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d
PE20080857A1 (es) * 2006-10-20 2008-08-19 Amgen Inc Formulaciones a base de polipeptidos estables
CN101600457B (zh) * 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
ES2378094T3 (es) * 2007-02-12 2012-04-04 Lassaad Boujbel Disolución de sucralosa estéril sin conservantes y su procedimiento de preparación
US20080311119A1 (en) * 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009003010A2 (en) * 2007-06-25 2008-12-31 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
EP2237038B1 (en) * 2007-10-22 2015-04-29 Becton Dickinson and Company Medical articles coated with organopolysiloxane containing a protein solution and non-ionic surfactant
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
US8772461B2 (en) 2008-04-15 2014-07-08 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
US8263748B2 (en) 2008-08-27 2012-09-11 Schering Corporation Lyophilized formulations of engineered anti-IL-23p19 antibodies
TWI445716B (zh) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
KR101275413B1 (ko) * 2008-12-29 2013-06-18 주식회사 삼양바이오팜 동결건조제형의 약제학적 조성물 및 그 제조방법
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
JP2013525260A (ja) * 2009-04-17 2013-06-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 急性骨髄性白血病を治療するための組成物および方法
EP2427211A4 (en) * 2009-05-04 2013-05-01 Abbott Biotech Ltd STABLE FORMULATIONS WITH HIGH PROTEIN CONCENTRATION OF ANTI-TNF-ALPHA HUMAN ANTIBODIES
KR101441768B1 (ko) * 2009-09-17 2014-09-17 박스터 헬쓰케어 에스에이 히알루로니다아제 및 면역글로불린의 안정한 복합제제, 및 그 사용방법
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP2013520476A (ja) * 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
WO2011130603A2 (en) 2010-04-16 2011-10-20 Biogen Idec Ma Inc. Anti-vla-4 antibodies
ES2993022T3 (en) 2010-05-28 2024-12-20 Novo Nordisk As Stable multi-dose compositions comprising an antibody and a preservative
DK2575870T3 (en) 2010-06-04 2017-02-13 Wyeth Llc vaccine Formulations
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120076779A1 (en) * 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
RS66261B1 (sr) 2010-10-25 2024-12-31 Biogen Ma Inc Postupci za određivanje razlika u aktivnosti alfa-4 integrina uspostavljanjem korelacije sa razlikama u nivoima svcam i/ili smadcam
ES2601202T3 (es) 2010-11-11 2017-02-14 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-TNT-alfa de alta concentración
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
SI2691112T1 (en) 2011-03-31 2018-07-31 Merck Sharp & Dohme Corp. STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
JP2014515367A (ja) * 2011-05-26 2014-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 不活性化デング熱ウイルスワクチン
EP2726090B1 (en) 2011-07-01 2020-01-01 Biogen MA Inc. Arginine - free tnfr : fc- fusion polypeptide compositions
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
MY164611A (en) * 2012-01-23 2018-01-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
EP3431104A1 (en) * 2012-03-26 2019-01-23 Sanofi Stable igg4 binding agent formulations
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HUE052447T2 (hu) 2013-09-08 2021-04-28 Kodiak Sciences Inc A VIII. tényezõs zwitterionos polimer konjugációk
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
EP3071237B1 (en) 2013-11-21 2024-06-26 Genmab A/S Antibody-drug conjugate lyophilised formulation
US9932591B2 (en) 2013-12-18 2018-04-03 University Of Delaware Reduction of lipase activity in product formulations
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TWI752912B (zh) * 2015-07-17 2022-01-21 美商寇西勒斯生物科技股份有限公司 那他珠單抗的穩定水性調配物
US10484453B2 (en) * 2015-07-29 2019-11-19 Xerox Corporation System and method for printing documents using print hardware and automatic context inference
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
JP2019505520A (ja) 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
RU2732109C2 (ru) 2016-02-10 2020-09-11 Бектон Дикинсон Франс Способ оценки стабильности композиции на основе белка
WO2018091729A2 (en) 2016-11-21 2018-05-24 Zaklady Farmaceutyczne Polpharma Sa Aqueous pharmaceutical formulations
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
EP3720483A2 (en) 2017-12-06 2020-10-14 Merck Sharp&Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2020005981A (es) * 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
EP3762015A4 (en) 2018-03-05 2022-04-27 Janssen Biotech, Inc. METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
US11667702B2 (en) 2018-03-08 2023-06-06 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
JP2021521168A (ja) * 2018-04-10 2021-08-26 ドクター レディズ ラボラトリーズ リミテッド 安定な抗体製剤
WO2019198100A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Antibody formulation
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2020004368A1 (ja) * 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
CN113395979A (zh) 2018-11-20 2021-09-14 詹森生物科技公司 用抗il-23特异性抗体治疗银屑病的安全且有效的方法
US20220296695A1 (en) 2018-12-19 2022-09-22 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20220088188A1 (en) * 2018-12-24 2022-03-24 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
WO2020245420A1 (en) * 2019-06-07 2020-12-10 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
US20220323583A1 (en) * 2019-06-11 2022-10-13 Macrogenics, Inc. Pharmaceutical Formulations of Bi-Specific Diabodies and Use of the Same
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114786724A (zh) * 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
IL294461A (en) * 2020-01-13 2022-09-01 Aptevo Res & Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
US20230077205A1 (en) * 2020-01-29 2023-03-09 Merck Sharp & Dohme Llc Methods of separating host cell lipases from an anti-lag3 antibody production
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
AU2023236910A1 (en) 2022-03-14 2024-08-01 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508132C3 (de) * 1974-03-08 1980-10-16 Teijin Ltd., Osaka (Japan) Verfahren zur Herstellung von Humanimmunglobulin-Derivaten und parenteral applizierbare Lösung hiervon
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
EP0417191B1 (en) * 1988-05-27 1993-03-10 Centocor, Inc. Formulation for antibody reagents
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US7435802B2 (en) * 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP1516628B1 (en) * 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
DE19912637A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
KR20060127247A (ko) 1999-03-25 2006-12-11 애보트 게엠베하 운트 콤파니 카게 항체 활성을 개선시키는 방법
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
PL201766B1 (pl) * 2001-01-31 2009-05-29 Roehm Gmbh Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
EP1409018B1 (en) * 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
AU2003211990A1 (en) * 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
EP1485127B1 (en) 2002-02-25 2011-06-08 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2515444C (en) * 2003-02-10 2014-04-01 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US7807187B2 (en) 2003-05-13 2010-10-05 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
NZ584288A (en) 2004-02-06 2011-10-28 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
US20080311119A1 (en) 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations

Also Published As

Publication number Publication date
DK3417875T3 (da) 2020-08-31
EP2236154B1 (en) 2018-05-30
EP1592440A2 (en) 2005-11-09
EP3777880A1 (en) 2021-02-17
EP2236154A1 (en) 2010-10-06
US10954303B2 (en) 2021-03-23
MY162623A (en) 2017-06-30
HK1182021A1 (en) 2013-11-22
CN1771053A (zh) 2006-05-10
US20130071386A1 (en) 2013-03-21
SI3417875T1 (sl) 2021-01-29
HUE051878T2 (hu) 2021-03-29
US8900577B2 (en) 2014-12-02
CA2515444A1 (en) 2004-08-26
CA2515444C (en) 2014-04-01
KR20050110628A (ko) 2005-11-23
TR201808801T4 (tr) 2018-07-23
MXPA05008409A (es) 2005-10-05
NO20054164L (no) 2005-09-07
WO2004071439A3 (en) 2005-07-07
SI2236154T1 (en) 2018-08-31
AU2010202254B2 (en) 2012-02-23
US8349321B2 (en) 2013-01-08
CN1771053B (zh) 2012-10-03
US20150044206A1 (en) 2015-02-12
UA82685C2 (uk) 2008-05-12
UY28184A1 (es) 2004-09-30
CY1120574T1 (el) 2019-07-10
TW200505478A (en) 2005-02-16
ES2819011T3 (es) 2021-04-14
EP1592440A4 (en) 2007-07-11
AR043144A1 (es) 2005-07-20
TWI367766B (en) 2012-07-11
JP2006517233A (ja) 2006-07-20
JP2011088913A (ja) 2011-05-06
PT2236154T (pt) 2018-06-26
US20180194843A1 (en) 2018-07-12
CN103040732B (zh) 2015-04-01
EP3417875B1 (en) 2020-06-17
JP4728948B2 (ja) 2011-07-20
AU2010202254A1 (en) 2010-06-24
NO346070B1 (no) 2022-01-31
SK50672005A3 (sk) 2006-03-02
RU2358763C2 (ru) 2009-06-20
RU2005128280A (ru) 2006-06-10
DK2236154T3 (en) 2018-06-25
IL170008A (en) 2015-05-31
US20120328614A1 (en) 2012-12-27
US20210292419A1 (en) 2021-09-23
WO2004071439A2 (en) 2004-08-26
EP3417875A1 (en) 2018-12-26
US20050053598A1 (en) 2005-03-10
PT3417875T (pt) 2020-08-24
ZA200506159B (en) 2006-10-25
PE20050190A1 (es) 2005-03-21
US8815236B2 (en) 2014-08-26
JP2014028831A (ja) 2014-02-13
CL2004000224A1 (es) 2005-01-21
AU2004210679A1 (en) 2004-08-26
CN103040732A (zh) 2013-04-17
US20100021461A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
CY1123667T1 (el) Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου
DE60125797D1 (de) Impfstoffzusammesetzung
CY1113353T1 (el) Φαρμακοτεχνικη μορφη αντι-τνf-αλφα αντισωματος
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
CY1113826T1 (el) Ανοσοενισχυτικα για εμβολια
UY26807A1 (es) Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos
CY1105779T1 (el) Εμβολιο ανθρωπινου ιου θηλωματων με αποσυγκροτημενα και επανασυγκροτημενα σωματιδια ομοιαζοντα με αυτα του ιου
CY1105389T1 (el) Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
CY1109034T1 (el) Τροποποιημενες κυτοκινες για χρηση σε θεραπεια καρκινου
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
PH12022552172A1 (en) High concentration anti-a㟠protofibril antibody formulations and methods of use thereof
EE05474B1 (et) Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks
DK1406642T3 (da) Fremgangsmåde til polyvalent bakteriofag-fremstilling til behandling af bakterielle infektioner
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
ES2166763T3 (es) Inmunizacion parenteral contra rotavirus.
DE602004015141D1 (de) Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe
DE60210936D1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
EA200300535A1 (ru) Способ получения антигенных структур, усиливающих специфическую перекрестную реактивность
CY1108852T1 (el) Φυσικο αντισωμα ενepγο κατα του ιου hiv
CY1116170T1 (el) Μεθοδος παρασκευης ανασυνδυασμενων αντισωματων εναντι ογκων
DE3586795D1 (de) Absorptionsverbesserer fuer proteine.